
The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial results show. “These results show that type 2 diabetes may be prevented, even in people who are on the verge of it, by using a medicine that causes weight loss,” researcher Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City, said in a news release. People with prediabetes have higher-than-normal blood sugar levels, but have not yet developed full-blown type 2 diabetes. Obesity is a risk factor both for prediabetes and for type 2 diabetes. For this clinical trial, more than 2,500 obese people were randomly assigned to receive one of three different doses of Zepbound, or a placebo, for more than three years. Of those patients, more than 1,000 had prediabetes. Zepbound (tirzepatide) in an injectable drug that activates receptors in the body for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors, researchers said. These receptors help slow digestion, reduce appetite and improve blood sugar control. GLP-1 drugs have been shown to promote significant weight loss. In this trial, patients taking Zepbound had lost 12% to 20% of their initial weight… read on > read on >